This article was originally published in The Gray Sheet
Raises $3.7 mil. from the exercise of "essentially all" of its 796,400 outstanding common stock purchase warrants, which were called April 7 for redemption and which expired May 13. Proceeds have "been infused" into the firm's working capital and will be used for clinicals and regulatory approval. The Milford, Massachusetts-based producer of medical laser systems is in Phase II clinicals of its Heart Laser for transmyocardial revascularization.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.